Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study

医学 封锁 结直肠癌 新辅助治疗 打开标签 肿瘤科 癌症 内科学 受体 临床试验 乳腺癌
作者
Gong Chen,Ying Jin,Wen‐Long Guan,Rongxin Zhang,Weiwei Xiao,Peiqiang Cai,Min Liu,Junzhong Lin,Fulong Wang,Cong Li,Ting-Ting Quan,Shaoyan Xi,Huizhong Zhang,Zhizhong Pan,Rui Wang,Rui‐Hua Xu
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier BV]
卷期号:8 (5): 422-431 被引量:143
标识
DOI:10.1016/s2468-1253(22)00439-3
摘要

Summary

Background

The current standard treatment for locally advanced rectal cancer is neoadjuvant chemoradiotherapy followed by radical surgery, but this approach can lead to multiple complications. We aimed to investigate the clinical activity and safety of neoadjuvant therapy with sintilimab, a single-agent PD-1 antibody, in patients with mismatch-repair deficient locally advanced rectal cancer.

Methods

This open-label, single-arm, phase 2 study was done at the Sun Yat-sen University Cancer Center, Guangzhou, China. Patients aged 18–75 years with mismatch-repair deficient or microsatellite instability-high locally advanced rectal cancer were enrolled and received neoadjuvant sintilimab monotherapy (200 mg by intravenous infusion) every 21 days. After an initial four cycles of treatment, patients and clinicians could choose one of the following options: total mesorectal excision surgery, followed by four cycles of adjuvant sintilimab with or without CapeOX chemotherapy (capecitabine 1000 mg/m2, orally administered twice daily on days 1–14; oxaliplatin 130 mg/m2, intravenously administered on day 1 every 3 weeks), determined by clinicians; or another four cycles of sintilimab followed by radical surgery or observation (only for patients with a clinical complete response; also known as the watch and wait strategy). The primary endpoint was the complete response rate, which included both a pathological complete response after surgery and a clinical complete response after completion of sintilimab treatment. Clinical response was evaluated by digital rectal examination, MRI, and endoscopy. Response was assessed in all patients who received treatment at least until the first tumour response assessment, after the first two cycles of sintilimab. Safety was analysed in all patients who received at least one dose of treatment. This trial is closed to enrolment and is registered with ClinicalTrials.gov (NCT04304209).

Findings

Between Oct 19, 2019, and June 18, 2022, 17 patients were enrolled and received at least one dose of sintilimab. The median age was 50 years (IQR 35–59) and 11 (65%) of 17 patients were male. One patient was excluded from efficacy analyses because they were lost to follow-up after the first sintilimab cycle. Of the remaining 16 patients, six underwent surgery, of whom three had a pathological complete response. Nine other patients had a clinical complete response and chose the watch and wait strategy. One patient had a serious adverse event and discontinued treatment; this patient did not have a complete clinical response and refused to undergo surgery. A complete response was thus noted for 12 (75%; 95% CI 47–92) of 16 patients. One of the three patients who underwent surgery but did not have a pathological complete response showed an increase in tumour volume after the initial four cycles of sintilimab (at which point they underwent surgery); this patient was deemed to have primary resistance to immune checkpoint inhibitors. After a median follow-up of 17·2 (IQR 8·2–28·5) months, all patients were alive and none had disease recurrence. Only one (6%) patient had a grade 3–4 adverse event, which was deemed a serious adverse event (grade 3 encephalitis).

Interpretation

The preliminary results of this study suggest that anti-PD-1 monotherapy is effective and tolerable for patients with mismatch-repair deficient locally advanced rectal cancer and could potentially spare some patients from radical surgery. Longer treatment courses might be needed to achieve maximum effects in some patients. Longer follow-up is also needed to observe the duration of response.

Funding

The National Natural Science Foundation of China, CAMS Innovation Fund for Medical Sciences, Science and Technology Program of Guangzhou, and Innovent Biologics.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
霹雳啪啦完成签到,获得积分10
刚刚
刚刚
1秒前
czf完成签到,获得积分10
1秒前
zzh发布了新的文献求助50
1秒前
2秒前
2秒前
2秒前
2秒前
2秒前
3秒前
3秒前
3秒前
Monarch完成签到 ,获得积分10
4秒前
姜丝罐罐n完成签到 ,获得积分10
5秒前
cc发布了新的文献求助20
6秒前
6秒前
6秒前
上官若男的应助被浮云采纳,获得10
8秒前
putao发布了新的文献求助10
9秒前
残梦完成签到 ,获得积分10
10秒前
CJJ发布了新的文献求助10
10秒前
10秒前
Owen的应助被高大橙采纳,获得10
10秒前
往事随风的应助被稳重续采纳,获得30
11秒前
Hello的应助被THESHY采纳,获得10
11秒前
今后的应助被EasonYao采纳,获得10
12秒前
12秒前
Cheryl发布了新的文献求助30
12秒前
木兮木完成签到 ,获得积分10
15秒前
neuro1993完成签到,获得积分10
15秒前
苏苏发布了新的文献求助10
15秒前
lll完成签到,获得积分10
16秒前
张译尹完成签到,获得积分10
17秒前
打打的应助被Monarch采纳,获得10
17秒前
dawn末黎完成签到,获得积分10
17秒前
HHH发布了新的文献求助10
18秒前
余籁完成签到,获得积分10
19秒前
20秒前
mochiho关注了科研通微信公众号
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179039
求助须知:如何正确求助?哪些是违规求助? 9569680
关于积分的说明 21805951
捐赠科研通 7774135
什么是DOI,文献DOI怎么找? 3432981
关于科研通互助平台的介绍 2556897
邀请新用户注册赠送积分活动 2478640